A US-based, NYSE-listed medical-devices maker focused on heart valves, transcatheter structural-heart therapies, and hemodynamic monitoring.
edwards.comLegal name
Edwards Lifesciences Corporation
Founded
1958
Headquarters
Irvine, California, USA
Industry
Medical devices (structural heart, cardiovascular)
Employees
16,000+ (2025)
CFO
Doretta (Theodora) Mistras
Revenue (FY25)
US$6.07 billion
Market cap
~US$48.75 billion (live figure at fetch)Listed on
NYSE: EW
Edwards Lifesciences Corporation is a US medical-devices company headquartered in Irvine, California, and founded in 1958. It specializes in structural heart disease, making tissue heart valves, transcatheter heart valve technologies, and hemodynamic monitoring systems. The company trades on the New York Stock Exchange under the ticker EW and is a component of the S&P 500.
The company reported revenue of about US$6.07 billion for 2025 and employs more than 16,000 people worldwide. It runs manufacturing operations in California and Utah in the US, along with facilities in Costa Rica, Singapore, and Ireland, and has announced a planned site in Spain. Its product lines cover transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies, surgical structural heart, and critical care monitoring.
Edwards is led by CEO Bernard J. Zovighian, who took the role in May 2023. Doretta Mistras became CFO in 2026, succeeding Scott Ullem. Nicholas J. Valeriani has served on the board since 2014.
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer, Corporate VP, Advanced Innovation & Technology
Corporate Vice President, General Counsel
Interview experience
Favorable (7/10)
Interview difficulty
Medium (4/10)
Interview process length
About a week (most common)
Practice real questions and get instant feedback before you walk in.
Q: Is English your first language?
A: This is a straightforward background question about communication on the floor. Answer honestly and mention any languages you speak comfortably at work.
Q: If there was an issue with a teammate, how would you go about it? Would you speak to your supervisor about it?
A: Show that you try a calm, direct conversation first and escalate to a supervisor when safety, quality, or output is at risk.
Q: On a production line, if someone does not feel well, do you stop your work to help or proceed with your own job while others take their turn?
A: Put the person's wellbeing first while following the line's stop-and-notify rules so quality and coverage are both protected.
Q: What does quality mean to you?
A: For a medical-devices maker, quality means every unit meets spec and is safe for a patient, with defects caught early instead of passed downstream.
Practice real questions and get instant feedback before you walk in.
Total comp
$93K to $165K+ (median $120K)
Total comp
$145K to $202K+ (median ~$145K)
E2 to E3
$103K to $143K
Total comp
$165K (median)
Total comp
$140K (median)
Total comp
$102K (median)
See how your target pay compares and find roles that match it.
Houston, TX • Full-time
San Francisco Bay Area, CA • Full-time
Irvine, CA • Full-time
Irvine, CA • Full-time
Salt Lake City, UT • Full-time
Irvine, CA • Full-time
Tailor your resume to each Edwards Lifesciences role in minutes.
July 16, 2026
Edwards to host Q2 2026 earnings conference call on July 23
Edwards Lifesciences said it will report operating results for the quarter ended June 30, 2026 after market close on July 23, 2026, followed by a conference call with management.
#earnings #investors #NYSE_EW
View postJune 26, 2026
Edwards showcases expanding structural heart evidence at New York Valves
Edwards presented new scientific data supporting its structural heart portfolio at the New York Valves conference, reinforcing its transcatheter and surgical valve leadership.
#structuralheart #clinicaldata #TAVR
View postMay 4, 2026
Edwards names Theodora Mistras as Chief Financial Officer
Edwards appointed Theodora "Doretta" Mistras as corporate vice president and CFO effective end of May 2026. She joined from Viatris, where she had served as CFO since March 2024, succeeding Scott Ullem.
#leadership #CFO #executive
View postMay 2, 2026
Ten-year data show long-term durability of Edwards' Resilia tissue
Edwards reported ten-year pivotal data demonstrating the long-term durability of its Resilia tissue technology used in surgical heart valves.
#Resilia #clinicaldata #heartvalves
View postApril 23, 2026
Edwards reports Q1 2026 sales up 16.7% and raises 2026 guidance
Q1 2026 sales rose 16.7% to $1.65 billion, with TAVR up 14.4% to $1.20 billion and TMTT at $173 million; adjusted EPS was $0.78. Edwards raised full-year sales growth guidance to 9% to 11%.
#earnings #TAVR #TMTT
View postEdwards Lifesciences is headquartered in Irvine, California, in the United States.
